Big4Bio

Subscribe FREE for daily biohub news covering the Boston, San Diego, San Francisco, Philadelphia, Los Angeles, New York City, Capital Region, and Seattle areas.

[Big4Bio @big4bio]

Top 10 U.S. Biopharma Clusters 2026 https://t.co/pPtGtePV5U via @GENbio #Big4Bio #biotech #lifesciences

[Big4Bio @big4bio]

This week's CEO Weekly Q&A: Robin Toft, CEO of @Curebound. A 20-year colon cancer survivor who went from patient to executive search founder to leading a $51.5M #cancerresearch accelerator in San Diego. Her story is unlike anything else in biotech leadership.

Read it: https://t.co/AjfUPcuUrW

[Big4Bio @big4bio]

On this week’s episode of “The Readout LOUD,” @statnews chats with longtime #biotech executive Jeremy Levin about his new book, “Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust.”

That sounds alarmist, and it is in some respects, but as Levin explains, the book is also a roadmap to a brighter future for the biotech industry.

https://t.co/O6HBXR4VWx

[Ginkgo Bioworks @Ginkgo]

Katia Riddle at @NPR went inside our Boston facility to witness Nebula, the world’s largest autonomous lab, in action. She spoke with our co-founders @jrkelly and @reshmapshetty about how autonomous labs are already shaping the future of scientific discovery.

🎧 Listen to the episode on All Things Considered: https://t.co/E4HUoypxDb

[Big4Bio @big4bio]

How to maximize cancer drug candidate potential through molecular radiotherapy

Explore the program framework, logistics, and critical research components for building IND-ready radiotherapies.

https://t.co/xJFT7Ml8QQ

#cancer #Radiopharmaceuticals #OncologyResearch #webinar

[Big4Bio @big4bio]

BIG4BIO WEEKLY CEO Q&A:
Maher Masoud, President & CEO, MaxCyte®

In this Q&A, Masoud reflects on what drew him to lead @MaxCyte_info, how its Flow Electroporation® platform and SeQure™ gene editing characterization services are enabling the next generation of cell therapies, and why the company positions itself not as a vendor but as an embedded partner in its customers’ success

https://t.co/IM6d8pYRTQ

#geneediting #sicklecelldisease

[Big4Bio @big4bio]

US taps small San Diego #biotech for experimental #Ebola treatment as epidemic worsens https://t.co/9HKwLfjgTX

[nature @Nature]

Artificial intelligence is rapidly accelerating scientific output, but risks narrowing inquiry, weakening judgement and undermining how scientists are trained

https://t.co/KFV2JYYhDJ

[phantomneuro @phantom_neuro]

Our Founder & CEO, @Connor_G_Glass, was featured in this week’s @big4bio LifeSci Startup CEO Q&A. He discussed Phantom X, our minimally invasive muscle-machine interface, and the importance of scalable #neurotech for patients.

🔗 Read more here: https://t.co/Hljrf0NEoL

[Big4Bio @big4bio]

Online Auction May 19-21, 2026
BioMarin West Coast Lab Restructure – California Multi-Site Event

Featuring Advanced Analytical, Sequencing & Processing Systems Across California—Highlighted by Illumina NovaSeq 6000, Sciex Zeno TOF 7600, and Complete Bioprocessing Solutions. San Rafael Assets Must Be Removed by June 16th—Plan Accordingly.

https://t.co/eADRqNI7af

[Big4Bio @big4bio]

Introducing The #Big4Bio CEO Weekly Q&A

Every Monday, we spotlight a life sciences CEO from one of our 8 coverage regions — their story, their science, their vision.

First feature is live now: Q&A with Sean McCarthy, CEO of @CytomXInc -- https://t.co/pzfPxsa5WD

CEOs & comms agencies: [email protected] to get featured. #lifesciences #biotech #CEO

[Big4Bio @big4bio]

MBC BioLabs bets on #AI boom to boost #biotech startups - San Francisco Business Times
https://t.co/tCvfDtEVvE via @SFBusinessTimes

#startups #lifesciences

[Matthew Herper @matthewherper]

Regenxbio says Duchenne gene therapy succeeded in clinical trial, paving way for FDA submission

https://t.co/EJ2QQJ0D2d via @statnews

[Big4Bio @big4bio]

Biotech’s #IPO tide is finally turning, thanks in part to the recent M&A surge
https://t.co/qKAQEFOj80

$COAG $SPTX $ODTX $AVLN

[Cambridge Healthtech Institute @CHI_Healthtech]

Join 400+ thought leaders and influencers from industry and academia who will convene at #NGDx in Washington, D.C. on August 24-26 to discuss #diagnostic advancement and technology innovation. Early-bird savings deadline extended until this Friday, May 15. https://t.co/0gMFiITuE5

[Big4Bio @big4bio]

Odyssey voyages to #Nasdaq with $304M #IPO to fund autoimmune, inflammatory pipeline

https://t.co/wpBenc289y

[nature @Nature]

Obituary: J Craig Venter (1946-2026) maverick biotechnologist who sequenced the human genome

https://t.co/da4g7Aeni5

[Eric Topol @EricTopol]

"The human genome encodes for a new category of molecule"
"The ‘dark proteome’ is upending our understanding of human disease"
@Nature
"Expanding the human proteome with microproteins and peptideins"
https://t.co/5ncSKGKHBH
https://t.co/2Rx65FJCbG @statnews @MeganMolteni
https://t.co/7mATxNQ1EO @TheEconomist

[Big4Bio @big4bio]

Entrada Therapeutics’ Duchenne muscular dystrophy (#DMD) data have fallen well short of expectations, crashing the #biotech’s stock as investors evaluated the fallout from a key readout expected to validate its platform.

https://t.co/ehvwqSZMID

$TRDA $NVS

[Big4Bio @big4bio]

Blackstone Life Sciences Invests $250 Million in Anagram Therapeutics

“We believe Anagram is well positioned to transform the treatment of pancreatic insufficiency, especially in patients of all ages who suffer from cystic fibrosis,” said Dr. Nicholas Galakatos, Global Head of Blackstone Life Sciences. “This is an excellent case study of our ownership strategy where we bring scale capital, deep domain expertise, and hands-on engagement to help address large unmet medical needs.”

https://t.co/MBTCvuVAhT

@anagramtx @blackstone #biotech #CF $BX